Alpha Tau's Pancreatic Cancer Trial Expands to 48 Patients Amid Strong Demand
Event summary
- Alpha Tau completed enrollment in its IMPACT pancreatic cancer study, expanding from 12 to 48 patients due to high demand.
- The study evaluates Alpha DaRT as a one-time add-on to standard chemotherapy for unresectable pancreatic cancer.
- Initial data from the study is expected in early 2027 and will inform the design of a planned pivotal study.
- IMPACT is part of a global pancreatic cancer program that includes the ACAPELLA trial in France and a study at the University of Verona.
The big picture
Alpha Tau's IMPACT study completion highlights the urgent need for innovative treatments in pancreatic cancer, a disease with limited therapeutic options. The study's expansion reflects both clinical demand and the potential of Alpha DaRT to complement existing chemotherapy regimens. As Alpha Tau advances its global pancreatic cancer program, the success of IMPACT could set the stage for broader adoption of its technology in oncology.
What we're watching
- Clinical Efficacy
- How the safety and efficacy data from IMPACT will position Alpha DaRT in the pancreatic cancer treatment landscape.
- Regulatory Pathway
- Whether the planned pivotal study will accelerate Alpha DaRT's path to commercialization.
- Competitive Dynamics
- The pace at which Alpha Tau can integrate Alpha DaRT with emerging systemic therapies in pancreatic cancer.
Related topics